Clinical trials recruiting in León, Spain

Phase breakdown

Conditions recruiting in León, Spain

Recruiting trials in León, Spain

• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
  NCT05708235 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
  NCT02819882 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
  NCT06686615 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  NCT06119581 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
  NCT07401381 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: Female
• AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
  NCT07503210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• DESTINY Breast Respond HER2-(Ultra)Low Europe
  NCT05945732 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
  NCT06446882 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
  NCT04898283 · Phase: Phase 3 · Ages: 12 Years to 65 Years · Sex: All (male and female)
• Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer
  NCT07195227 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
  NCT06382948 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female)
• Measurement Properties of the Walking Adaptability Ladder Test and Foot Tap Test in Multiple Sclerosis
  NCT07505355 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female)
• OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
  NCT06068049 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
  NCT06078384 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
  NCT06315010 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry
  NCT06620757 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
  NCT06712355 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  NCT06712316 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry
  NCT05673681 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
  NCT06431633 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
  NCT07039110 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
  NCT05712200 · Phase: Phase 3 · Ages: 65 Years and older · Sex: All (male and female)
• The Fourth Left Atrial Appendage Occlusion Study
  NCT05963698 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• The ReTAVI Prospective Observational Registry
  NCT05601453 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• WATCHMAN FLX Pro European Registry
  NCT07262255 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in León, Spain?

30 recruiting trials have at least one study site in León, Spain.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.